Ann: Quarterly Report - September 2015, page-15

First 15 Last

Share
Profile

Follow
michaelbellamy

913 Posts.

55

18/11/15

13:54

Post #: 16423785
Share

Originally posted by imspartacus ↑

Medivet is still generating 2m+ annual revenue (increasing YoY) and signing new clinics up to stem-cell procedures, whilst continuing its partnership with universities on new animal therapies and vaccines (cancer) . IMO, There still seems like significant potential for the business, although MLA is increasingly looking like the incorrect operator to extract value.

I personally don't think it's worth walking away from the business for nothing, however perhaps stemming (no pun intended) the flow expenditure on that side of the business, cutting back (or delaying) on all none core research expenses, ie establishment of new labs etc and looking to boost revenue to attempt to get as close to self-funding as possible in the meantime might allow MLA to carry the business until the right suitor presents.

The loss attributable to the Medivet business seems loosely estimated around 1mill p.a, this is getting closer to being offset by the expanding human healthcare business. There is potential with quarterly revenue growing as it has and no further 'one offs' impacting the human business, that the overall business reaches a cash flow positive position in the next quarter.

I'm still projecting a sell of 50.5% for $2.5m, whilst retaining a 10% stake and a preferred arrangement on any equipment manufacture, though I think its unlikely to take place until sometime early in 2016 now.

All IMO, DYOR etc....

Expand

I still think medivet can be successfull in the near future ,however,mla has not the ability to follow through financially.If we could strike a deal and retain 20% free carried or the likes it could be a bonus in the years to come.
I still hold a positive view on a good outcome and believe it is good buying here.

MLA Price at posting: 6.6¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

FG1

Flynn Gold flags mid-grade drill hits and always eye-catching rock chips

MCT

Metalicity looking for offers on Admiral Bay zinc project

AI stocks: What to expect in 2024-25

LKE

Lake Resources implies news article on job cuts made up; non-core sales "not material" and no rule 15.7 breach

IMR

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Talking Australia's very competitive property landscape: Realty Talks

Warren Tredrea’s weekly sports business wrap: the latest on business in sport

GNX

NSW approves J-POWER's $380M buyout of Genex Power, giving it ownership of QLD net zero project

Wealth Within considers potential takeover targets in Australia's booming infrastructure industry

Week 29 Wrap: Trump in spotlight again; China's Third Plenum a yawnfest; RBA's August move a mystery